Enhanced immune response and protection efficacy of a DNA vaccine constructed by linkage of the Mycobacterium tuberculosis Ag85B-encoding gene with the BVP22-encoding gene

Journal of Medical Microbiology

Volumn 58, Issue 4, 2009, Pages 462-468

  Yao, Wanhong ^a   Liu, Shengwu ^a   Qu, Xueju ^a   Xiao, Shaobo ^b   Liu, Yan ^a   Liu, Junyan ^a,c  

^a WUHAN UNIVERSITY   (China)

^b HUAZHONG AGRICULTURAL UNIVERSITY   (China)

^c WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AG85B PROTEIN; ANTIBODY; BCG VACCINE; DNA; DNA VACCINE; GAMMA INTERFERON; PLASMID DNA; PROTEIN VP22; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; IMMUNOGLOBULIN G;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL GENE; BACTERIUM DETECTION; BCG VACCINATION; BOVINE HERPES VIRUS; CONTROLLED STUDY; DNA IMMUNIZATION; DNA VECTOR; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENE FUSION; GENETIC LINKAGE; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; LUNG; LYMPHOCYTE PROLIFERATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SECRETORY CELL; SINGLE DRUG DOSE; SPLEEN; SPLEEN LYMPHOCYTE; TUBERCULOSIS; ANIMAL; BIOSYNTHESIS; BLOOD; C57BL MOUSE; CELL PROLIFERATION; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; HELA CELL; HUMAN; IMMUNOLOGY; LYMPHOCYTE; METABOLISM; PATHOLOGY; RANDOMIZATION; STANDARD;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, BACTERIAL; GENES, BACTERIAL; HELA CELLS; HUMANS; IMMUNOGLOBULIN G; INTERFERON-GAMMA; LUNG; LYMPHOCYTES; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; RANDOM ALLOCATION; SPLEEN; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, DNA;

EID: 65649097326     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.004267-0     Document Type: Article

References (38)

1. Andersen, P. (2007). Tuberculosis vaccines - an update. Nat Rev Microbiol 5, 484-487.
2. Andersen, P. & Doherty, T. M. (2005). The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol 3, 656-662. (Pubitemid 41052152)
3. Braun, R. P., Payne, L. G. & Dong, L. C. (2006). Characterization of the IFN-γ T-cell responses to immediate early antigens in humans with genital herpes. Virol J 3, 54-68.
4. Elliott, G. & O'Hare, P. (1997). Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 88, 223-233. (Pubitemid 28015871)
5. Gupta, U. D., Katoch, V. M. & McMurray, D. N. (2007). Current status of TB vaccines. Vaccine 25, 3742-3751.
6. Harms, J. S., Ren, X. D., Oliveira, S. C. & Splitter, G. A. (2000). Distinctions between bovine herpesvirus 1 and herpes simplex virus type 1 VP22 tegument protein subcellular associations. J Virol 74, 3301-3312. (Pubitemid 30143755)
7. Hesseling, A. C., Schaaf, H. S., Hanekom, W. A., Beyers, N., Cotton, M. F., Gie, R. P., Marais, B. J., van Helden, P. & Warren, R. M. (2003). Danish Bacille Calmette-Guérin vaccine-induced disease in human immunodeficiency virus-infected children. Clin Infect Dis 37, 1226-1233. (Pubitemid 37372513)
8. Hesseling, A. C., Marais, B. J., Gie, R. P., Schaaf, H. S., Fine, P. E. M., Godfrey-Faussett, P. & Beyers, N. (2007). The risk of disseminated Bacille Calmette-Guérin (BCG) disease in HIV-infected children. Vaccine 25, 14-18. (Pubitemid 44855247)
9. Hung, C. F., Cheng, W. F., Chai, C. Y., Hsu, K. F., He, L. M., Ling, M. & Wu, T. C. (2001). Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. J Immunol 166, 5733-5740. (Pubitemid 32374199)
10. Hung, C. F., He, L. M., Juang, J., Lin, T. J., Ling, M. & Wu, T. C. (2002). Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen. J Virol 76, 2676-2682. (Pubitemid 34184853)
11. Ju, W., Liu, J., Xiao, W., Liu, M. & Qu, X. (2005). Construction of a eukaryotic expression system of HSP65 gene from Mycobacterium tuberculosis, and anti-HSP65 IgG produced in mice. J Med Microbiol 54, 3-6.
12. Kamath, A. T., Feng, C. G., MacDonald, M., Briscoe, H. & Britton, W. J. (1999). Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect Immun 67, 1702-1707. (Pubitemid 29144386)
13. Kaufmann, S. H. E. (2007). The contribution of immunology to the rational design of novel antibacterial vaccines. Nat Rev Microbiol 5, 491-504. (Pubitemid 46925378)
14. Kim, T. W., Hung, C.-F., Kim, J. W., Juang, J., Chen, P.-J., He, L. M., Boyd, D. A. K. & Wu, T.-C. (2004). Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity. Hum Gene Ther 15, 167-177. (Pubitemid 38210532)
15. Ko, H. J., Ko, S. Y., Kim, Y. J., Lee, E. G., Cho, S. N. & Kang, C. Y. (2005). Optimization of codon usage enhances the immunogenicity of a DNA vaccine encoding mycobacterial antigen Ag85B. Infect Immun 73, 5666-5674. (Pubitemid 41193002)
16. Lemken, M. L., Wolf, C., Wybranietz, W. A., Schmidt, U., Smirnow, I., Buhring, H. J., Mack, A. F., Lauer, U. M. & Bitzer, M. (2007a). Evidence for intercellular trafficking of VP22 in living cells. Mol Ther 15, 310-319. (Pubitemid 46111881)
17. Lemken, M.-L., Graepler, F., Wolf, C., Wybranietz, W. A., Smirnow, I., Schmidt, U., Gregor, M., Bitzer, M. & Lauer, U. M. (2007b). Fusion of HSV-1VP22 to a bifunctional chimeric SuperCD suicide gene compensates for low suicide gene transduction efficiencies. Int J Oncol 30, 1153-1161.
18. Liu, B., Liu, S., Qu, X. & Liu, J. (2006). Construction of a eukaryotic expression system for granulysin and its protective effect in mice infected with Mycobacterium tuberculosis. J Med Microbiol 55, 1389-1393. (Pubitemid 44651666)
19. Lozes, E., Huygen, K., Content, J., Denis, O., Montgomery, D. L., Yawman, A. M., Vandenbussche, P., Van Vooren, J. P., Drowart, A. & other authors (1997). Immunogenicity and efficacy of a tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex. Vaccine 15, 830-833. (Pubitemid 27287968)
20. Michel, N., Osen, W., Gissmann, L., Schumacher, T. N. M., Zentgraf, H. & Muller, M. (2002). Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination. Virology 294, 47-59. (Pubitemid 34921288)
21. Mitsuyama, M. & McMurray, D. N. (2007). Tuberculosis: vaccine and drug development. Tuberculosis (Edinb) 87, S10-S13.
22. + T cells using VP22 DNA vaccine vectors that promote intercellular spreading following initial transfection. J Leukoc Biol 78, 401-411.
23. Mwangi, W., Brown, W. C., Splitter, G. A., Davies, C. J., Howard, C. J., Hope, J. C., Aida, Y., Zhuang, Y., Hunter, B. J. & Palmer, G. H. (2007). DNA vaccine construct incorporating intercellular trafficking and intracellular targeting motifs effectively primes and induces memory B- and T-cell responses in outbred animals. Clin Vaccine Immunol 14, 304-311. (Pubitemid 46570289)
24. Oliveira, S. C., Harms, J. S., Afonso, R. R. & Splitter, G. A. (2001). A genetic immunization adjuvant system based on BVP22-antigen fusion. Hum Gene Ther 12, 1353-1359. (Pubitemid 32681849)
25. Phelan, A., Elliott, G. & O'Hare, P. (1998). Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat Biotechnol 16, 440-443. (Pubitemid 28211195)
26. Qiu, Z. H., Harms, J. S., Zhu, J. & Splitter, G. A. (2004). Bovine herpesvirus tegument protein VP22 enhances thymidine kinase/ ganciclovir suicide gene therapy for neuroblastomas compared to herpes simplex virus VP22. J Virol 78, 4224-4233. (Pubitemid 38437227)
27. Reece, S. T. & Kaufmann, S. H. E. (2008). Rational design of vaccines against tuberculosis directed by basic immunology. Int J Med Microbiol 298, 143-150. (Pubitemid 350216548)
28. Saha, S., Yoshida, S., Ohba, K., Matsui, K., Matsuda, T., Takeshita, F., Umeda, K., Tamura, Y., Okuda, K. & other authors (2006). A fused gene of nucleoprotein (NP) and herpes simplex virus genes (VP22) induces highly protective immunity against different subtypes of influenza virus. Virology 354, 48-57. (Pubitemid 44441505)
29. Sander, C. & McShane, H. (2007). Translational mini-review series on vaccines: development and evaluation of improved vaccines against tuberculosis. Clin Exp Immunol 147, 401-411. (Pubitemid 46208040)
30. Teixeira, F. M., Teixeira, H. C., Ferreira, A. P., Rodrigues, M. F., Azevedo, V., Macedo, G. C. & Oliveira, S. C. (2006). DNA vaccine using Mycobacterium bovis Ag85B antigen induces partial protection against experimental infection in BALB/c Mice. Clin Vaccine Immunol 13, 930-935. (Pubitemid 44409633)
31. Ulmer, J. B., Liu, M. A., Montgomery, D. L., Yawman, A. M., Deck, R. R., DeWitt, C. M., Content, J. & Huygen, K. (1997). Expression and immunogenicity of Mycobacteriun tuberculosis antigen 85B by DNA vaccination. Vaccine 15, 792-794. (Pubitemid 27287957)
32. Ulmer, J. B., Wahren, B. & Liu, M. A. (2006). Gene-based vaccines: recent technical and clinical advances. Trends Mol Med 12, 216-221. (Pubitemid 43728411)
33. WHO (2007). Global advisory committee on vaccine safety, 29-30 November 2006. Wkly Epidemiol Rec 82, 18-24.
34. Young, D. & Dye, C. (2006). The development and impact of tuberculosis vaccines. Cell 124, 683-687.
35. Zakhartchouk, A. N., Viswanathan, S., Moshynskyy, I., Petric, M. & Babiuk, L. A. (2007). Optimization of a DNA vaccine against SARS. DNA Cell Biol 26, 721-726.
36. Zavaglia, D., Favrot, M.-C., Eymin, B., Tenaud, C. & Coll, J.-L. (2003). Intercellular trafficking and enhanced in vivo antitumour activity of a nonvirally delivered P27-VP22 fusion protein. Gene Ther 10, 314-325. (Pubitemid 36305600)
37. Zheng, C. F., Babiuk, L. A. & Littel-Van Den Hurk, S. V. (2005). Bovine herpesvirus 1 VP22 enhances the efficacy of a DNA vaccine in cattle. J Virol 79, 1948-1953.
38. Zheng, C. F., Brownlie, R., Huang, D. Y., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. (2006). Intercellular trafficking of the major tegument protein VP22 of bovine herpesvirus-1 and its application to improve a DNA vaccine. Arch Virol 151, 985-993.